Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney.

Roksnoer LCW, Uijl E, de Vries R, Garrelds IM, Jan Danser AH.

Eur J Pharmacol. 2018 Apr 5;824:128-132. doi: 10.1016/j.ejphar.2018.02.007. Epub 2018 Feb 9.

PMID:
29432709
2.

Urinary renin-angiotensin markers in polycystic kidney disease.

Salih M, Bovée DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F874-F881. doi: 10.1152/ajprenal.00209.2017. Epub 2017 Jul 26.

3.

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.

Kwakernaak AJ, Roksnoer LC, Lambers Heerspink HJ, van den Berg-Garrelds I, Lochorn GA, van Embden Andres JH, Klijn MA, Kobori H, Danser AH, Laverman GD, Navis GJ.

PLoS One. 2017 Jan 24;12(1):e0169258. doi: 10.1371/journal.pone.0169258. eCollection 2017.

4.

Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye.

Prasad T, Roksnoer LC, Zhu P, Verma A, Li Y, Batenburg WW, de Vries R, Danser AH, Li Q.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6722-6730. doi: 10.1167/iovs.16-20289.

5.

From ARB to ARNI in Cardiovascular Control.

Uijl E, Roksnoer LC, Hoorn EJ, Danser AH.

Curr Hypertens Rep. 2016 Dec;18(12):86. Review.

6.

Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.

Roksnoer LC, van Veghel R, van Groningen MC, de Vries R, Garrelds IM, Bhaggoe UM, van Gool JM, Friesema EC, Leijten FP, Hoorn EJ, Danser AH, Batenburg WW.

Clin Sci (Lond). 2016 Jul 1;130(14):1209-20. doi: 10.1042/CS20160197. Epub 2016 Apr 19.

PMID:
27129187
7.

On the Origin of Urinary Renin: A Translational Approach.

Roksnoer LC, Heijnen BF, Nakano D, Peti-Peterdi J, Walsh SB, Garrelds IM, van Gool JM, Zietse R, Struijker-Boudier HA, Hoorn EJ, Danser AH.

Hypertension. 2016 May;67(5):927-33. doi: 10.1161/HYPERTENSIONAHA.115.07012. Epub 2016 Feb 29.

8.

Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Roksnoer LC, van Veghel R, de Vries R, Garrelds IM, Bhaggoe UM, Friesema EC, Leijten FP, Poglitsch M, Domenig O, Clahsen-van Groningen MC, Hoorn EJ, Jan Danser AH, Batenburg WW.

Kidney Int. 2015 Jul;88(1):109-20. doi: 10.1038/ki.2015.107. Epub 2015 Apr 1.

PMID:
25830765
9.

Renal angiotensin-converting enzyme upregulation: a prerequisite for nitric oxide synthase inhibition-induced hypertension?

Roksnoer LC, Hoorn EJ, Danser AH.

J Am Soc Nephrol. 2014 Dec;25(12):2679-81. doi: 10.1681/ASN.2014060549. Epub 2014 Jul 10. No abstract available.

10.

Methodologic issues in the measurement of urinary renin.

Roksnoer LC, Verdonk K, Garrelds IM, van Gool JM, Zietse R, Hoorn EJ, Danser AH.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1163-7. doi: 10.2215/CJN.12661213. Epub 2014 Apr 17.

11.

Branched-chain amino acid requirements for enterally fed term neonates in the first month of life.

de Groof F, Huang L, van Vliet I, Voortman GJ, Schierbeek H, Roksnoer LC, Vermes A, Chen C, Huang Y, van Goudoever JB.

Am J Clin Nutr. 2014 Jan;99(1):62-70. doi: 10.3945/ajcn.112.038927. Epub 2013 Nov 27.

PMID:
24284437
12.

The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice.

Lu X, Roksnoer LC, Danser AH.

Nephrol Dial Transplant. 2013 Dec;28(12):2977-82. doi: 10.1093/ndt/gft333. Epub 2013 Jul 30. Review.

PMID:
23901049
13.

Urinary markers of intrarenal renin-angiotensin system activity in vivo.

Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH.

Curr Hypertens Rep. 2013 Apr;15(2):81-8. doi: 10.1007/s11906-012-0326-z. Review.

PMID:
23296471

Supplemental Content

Loading ...
Support Center